ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Nanoparticle-Modified Nanofibers Induce Ferroptosis and Stimulate Antitumor Immunity for Melanoma Therapy.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Single-cell sequencing-guided design of synergistic chemo-immunotherapy nanodrugs for cGAS-STING activation in prostate cancer therapy.Journal of nanobiotechnology · 2026Article
- Metal-polyphenol nanomedicines for malignant tumor therapy.Frontiers in chemistry · 2026Review
- Nanoparticle-Modified Nanofibers Induce Ferroptosis and Stimulate Antitumor Immunity for Melanoma Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Precise delivery and controlled release: strategies and advances in TLR7/8 agonist prodrugs for cancer immunotherapy.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Melanoma, a highly aggressive and therapy-resistant cutaneous malignancy, presents formidable clinical challenges owing to its propensity for early metastasis and frequent postoperative recurrence. Here, a nanofiber-based drug delivery system (5F/STFM/R-ES) is developed that synergistically induces ferroptosis and potentiates immunotherapy to inhibit melanoma growth and reduce the risk of metastasis and recurrence. To this end, mesoporous silica nanoparticles encapsulating resiquimod (R848) are surface-coated with Fe/Mn-based metal-polyphenol networks (TFM) to form STFM/R. Subsequently, STFM/R is electrospun into 5-fluorouracil-loaded nanofibers. When applied to the tumor site, 5-fluorouracil and STFM/R are released. Following the degradation of STFM/R, the release of Fe
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.